American Academy of HIV Medicine | Clinical Research Update 5.7.24
by Carolyn Chu, MD, MSc, AAHIVS, AAHIVM Chief Medical Officer Featured Literature: Lake JE, Kitch DW, Kantor A, et al. The effect of open-label semaglutide on metabolic dysfunction-associated steatotic liver disease in people with HIV. Ann Intern Med. 2024 Apr 30. doi: 10.7326/M23-3354. PMID: 3868410 0. The SLIM LIVER team investigated whether semaglutide taken as 1mg weekly was associated with changes in liver fat and cardiometabolic parameters among adult PWH with central adiposity, insulin resistance/pr